PASADENA, Calif. --(BUSINESS WIRE)--Jul. 9, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on July 28, 2020 , at 12:00 p.m. EDT it will host a key opinion leader webinar on ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a

PASADENA, Calif. --(BUSINESS WIRE)--Jul. 8, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 5, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal third quarter ended June 30, 2020 .

PASADENA, Calif. --(BUSINESS WIRE)--May 28, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Jefferies Virtual Healthcare Conference – June 2-4, 2020 June 4 , 2:00 p.m.

- Conference Call and Webcast Today, May 7 at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2020 . The company is hosting a conference call at 4:30 p.m.

PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2020 Health Care Conference – May 12-14, 2020 May 14 , 11:00 a.m.

PASADENA, Calif. --(BUSINESS WIRE)--May 1, 2020-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the retirement of Bruce Given , M.D., Arrowhead’s chief operating officer and head of R&D, which was previously planned and disclosed, after a more than 30-year career in biotechnology

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 22, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2020 , at 4:30 p.m. EDT to discuss its financial results for the fiscal second quarter ended March 31, 2020 .

PASADENA, Calif. --(BUSINESS WIRE)--Apr. 10, 2020-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a

PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 11, 2020 , the Compensation Committee of the Board of Directors approved "inducement" grants to 31 new employees under Rule

PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and patients involved in ongoing clinical studies of